Sage Group Advises APR on InLicensing and Acquisition of Novel Pharma Products

ABOUT APR

Applied Pharma Research s.a. (www.apr.ch; “APR” or the “Company”) is a profitable, well-financed, privately held, Swiss developer of specialty healthcare products, with over 20 years of experience. APR has a proven track record in successfully developing and marketing novel products in various therapeutic areas on a global basis. APR identifies, in-licenses, develops (using 'state-of-the-art' technology, innovative formulations, dosage forms and delivery systems) and then commercializes through partners, science driven, branded products with unique selling points designed to address patient needs in niche or rare therapy areas.

APR’s business strategy starts from an understanding of the needs of various stakeholders and it then translates into product development the best products that address such needs. Product development is not restrained by the use of APR’s technologies. APR searches for the most innovative technologies available in the marketplace and it enters into co-development partnership with the originators of the technology for the development of the products. Finished products, and not technologies, are APR’s main focus.

APR OBJECTIVES

APR seeks to develop mutually profitable relationships with companies around the globe based on its partner’s products and technologies coupled with APR’s technological, developmental and regulatory expertise. By leveraging the combination of APR’s and its partner’s assets and capabilities, APR plans to continues its successful track record of out-licensing the resulting unique products. The ideal product is one regulated under the FDA’s 505(b2) pathway with a distinctive USP (Unique Selling Proposition), under development and/or fully developed, with a maximum 3-year time to market and potentially revenues in the US in any of the following broad fields.

Wound management
Niche pain and inflammation indications
Gastrointestinal
Rare diseases
Supportive care

Benefits of working with APR

APR employs a proven business model offering high potential and low risk for its partners. This includes:

Strong network of international partners in 70 markets
Strong formulation knowhow and ability to develop innovative dosage forms
Experienced management team.
Strong financial backers
Centrally managed operations with focus on in-house and high quality core competencies
Global development, regulatory and licensing capabilities
Committed to patients and partners.

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells

D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner

Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

The Sage Group: 30 Years of Successful Bioscience Transactions

Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)